Latest news

Xoma scoops up struggling biotechs HilleVax and Lava in bargain deals

Xoma scoops up struggling biotechs HilleVax and Lava in bargain deals

Joachim Eeckhout
Praxis touts epilepsy drug gains despite 23% dropout rate

Praxis touts epilepsy drug gains despite 23% dropout rate

Joachim Eeckhout
Daily Snap - 17. July 2025

Daily Snap - 17. July 2025

Joachim Eeckhout
Sarepta slashes workforce, scales back research after Duchenne gene therapy setbacks

Sarepta slashes workforce, scales back research after Duchenne gene therapy setbacks

Joachim Eeckhout
Otsuka continues its bet on autoimmune therapies with $613M Cantargia antibody deal

Otsuka continues its bet on autoimmune therapies with $613M Cantargia antibody deal

Joachim Eeckhout
WHO adds ArkBio ́s RSV drug to its priority list

WHO adds ArkBio ́s RSV drug to its priority list

Eduardo Longoria
AstraZeneca’s new blood pressure drug bought from CinCor clears major trial

AstraZeneca’s new blood pressure drug bought from CinCor clears major trial

Joachim Eeckhout
China grabs 32% of global biotech deal value in 2025 surge

China grabs 32% of global biotech deal value in 2025 surge

Joachim Eeckhout
Daily Snap - 15. July 2025

Daily Snap - 15. July 2025

Joachim Eeckhout
Biotech job cuts continue as three more companies slash workforces

Biotech job cuts continue as three more companies slash workforces

Joachim Eeckhout
FDA rejects Capricor’s Duchenne cell therapy, citing lack of proven benefit

FDA rejects Capricor’s Duchenne cell therapy, citing lack of proven benefit

Joachim Eeckhout
Daily Snap - 14. July 2025

Daily Snap - 14. July 2025

Joachim Eeckhout
FirstBack
1718192021222324
Next Last